Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma Tumors

Chlorotoxin (CTX) is a 36-amino-acid disulfide-containing peptide derived from the venom of the scorpion <i>Leiurus quinquestriatus</i>. CTX alters physiology in numerous ways. It interacts with voltage gated chloride channels, Annexin-2, and matrix metalloproteinase-2 (MMP-2). CTX-based...

Full description

Bibliographic Details
Main Authors: Gadi Cohen, Scott R. Burks, Joseph A. Frank
Format: Article
Language:English
Published: MDPI AG 2018-11-01
Series:Toxins
Subjects:
Online Access:https://www.mdpi.com/2072-6651/10/12/496
id doaj-62dad75cd4c54a2ea2a78de9e2b512c3
record_format Article
spelling doaj-62dad75cd4c54a2ea2a78de9e2b512c32020-11-24T20:53:34ZengMDPI AGToxins2072-66512018-11-01101249610.3390/toxins10120496toxins10120496Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma TumorsGadi Cohen0Scott R. Burks1Joseph A. Frank2Frank Laboratory, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USAFrank Laboratory, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USAFrank Laboratory, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USAChlorotoxin (CTX) is a 36-amino-acid disulfide-containing peptide derived from the venom of the scorpion <i>Leiurus quinquestriatus</i>. CTX alters physiology in numerous ways. It interacts with voltage gated chloride channels, Annexin-2, and matrix metalloproteinase-2 (MMP-2). CTX-based bioconjugates have been widely subjected to phase I/II clinical trials and have shown substantial promise. Many studies have demonstrated that CTX preferentially binds to neuroectodermal tumors, such as glioblastoma, without cross-reactivity to normal brain cells. With its ability to penetrate the blood-brain-barrier (BBB) and its tyrosine residue allows covalent conjugation with functional moieties, CTX is an attractive platform to explore development of diagnostic and therapeutic agents for gliomas. In this review, we outline CTX structure and its molecular targets, summarize molecular variations of CTX developed for glioma imaging, and discuss future trends and perspectives for CTX conjugates as a theranostic agent.https://www.mdpi.com/2072-6651/10/12/496chlorotoxinglioblastomaimaging modalities
collection DOAJ
language English
format Article
sources DOAJ
author Gadi Cohen
Scott R. Burks
Joseph A. Frank
spellingShingle Gadi Cohen
Scott R. Burks
Joseph A. Frank
Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma Tumors
Toxins
chlorotoxin
glioblastoma
imaging modalities
author_facet Gadi Cohen
Scott R. Burks
Joseph A. Frank
author_sort Gadi Cohen
title Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma Tumors
title_short Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma Tumors
title_full Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma Tumors
title_fullStr Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma Tumors
title_full_unstemmed Chlorotoxin—A Multimodal Imaging Platform for Targeting Glioma Tumors
title_sort chlorotoxin—a multimodal imaging platform for targeting glioma tumors
publisher MDPI AG
series Toxins
issn 2072-6651
publishDate 2018-11-01
description Chlorotoxin (CTX) is a 36-amino-acid disulfide-containing peptide derived from the venom of the scorpion <i>Leiurus quinquestriatus</i>. CTX alters physiology in numerous ways. It interacts with voltage gated chloride channels, Annexin-2, and matrix metalloproteinase-2 (MMP-2). CTX-based bioconjugates have been widely subjected to phase I/II clinical trials and have shown substantial promise. Many studies have demonstrated that CTX preferentially binds to neuroectodermal tumors, such as glioblastoma, without cross-reactivity to normal brain cells. With its ability to penetrate the blood-brain-barrier (BBB) and its tyrosine residue allows covalent conjugation with functional moieties, CTX is an attractive platform to explore development of diagnostic and therapeutic agents for gliomas. In this review, we outline CTX structure and its molecular targets, summarize molecular variations of CTX developed for glioma imaging, and discuss future trends and perspectives for CTX conjugates as a theranostic agent.
topic chlorotoxin
glioblastoma
imaging modalities
url https://www.mdpi.com/2072-6651/10/12/496
work_keys_str_mv AT gadicohen chlorotoxinamultimodalimagingplatformfortargetinggliomatumors
AT scottrburks chlorotoxinamultimodalimagingplatformfortargetinggliomatumors
AT josephafrank chlorotoxinamultimodalimagingplatformfortargetinggliomatumors
_version_ 1716797027857203200